Fisher & Paykel Healthcare Valuation
Is FPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FPH (NZ$39.21) is trading above our estimate of fair value (NZ$22.43)
Significantly Below Fair Value: FPH is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FPH?
Key metric: As FPH is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is FPH's PS Ratio? | |
|---|---|
| PS Ratio | 13.2x |
| Sales | NZ$1.74b |
| Market Cap | NZ$22.60b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 13x |
| Enterprise Value/EBITDA | 51x |
| PEG Ratio | 7x |
Price to Sales Ratio vs Peers
How does FPH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.4x | ||
EBO EBOS Group | 0.5x | 1.0% | NZ$7.3b |
BIM bioMérieux | 3x | 7.3% | €11.6b |
SN. Smith & Nephew | 1.9x | 5.0% | UK£8.6b |
6869 Sysmex | 4.1x | 8.0% | JP¥2.0t |
FPH Fisher & Paykel Healthcare | 13.2x | 10.8% | NZ$22.6b |
Price-To-Sales vs Peers: FPH is expensive based on its Price-To-Sales Ratio (13.2x) compared to the peer average (2.4x).
Price to Sales Ratio vs Industry
How does FPH's PS Ratio compare vs other companies in the Oceanian Medical Equipment Industry?
| 9 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 9 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: FPH is expensive based on its Price-To-Sales Ratio (13.2x) compared to the Oceanic Medical Equipment industry average (4.9x).
Price to Sales Ratio vs Fair Ratio
What is FPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 13.2x |
| Fair PS Ratio | 12.4x |
Price-To-Sales vs Fair Ratio: FPH is expensive based on its Price-To-Sales Ratio (13.2x) compared to the estimated Fair Price-To-Sales Ratio (12.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | NZ$39.21 | NZ$31.19 -20.5% | 20.4% | NZ$41.80 | NZ$20.14 | n/a | 13 |
| Nov ’25 | NZ$36.07 | NZ$30.91 -14.3% | 19.3% | NZ$39.20 | NZ$20.14 | n/a | 13 |
| Oct ’25 | NZ$34.99 | NZ$30.91 -11.6% | 19.3% | NZ$39.20 | NZ$20.14 | n/a | 13 |
| Sep ’25 | NZ$35.60 | NZ$29.85 -16.2% | 18.7% | NZ$38.20 | NZ$20.14 | n/a | 13 |
| Aug ’25 | NZ$32.85 | NZ$25.89 -21.2% | 12.3% | NZ$32.80 | NZ$20.14 | n/a | 13 |
| Jul ’25 | NZ$29.95 | NZ$25.95 -13.4% | 11.9% | NZ$32.80 | NZ$20.14 | n/a | 14 |
| Jun ’25 | NZ$29.50 | NZ$25.95 -12.0% | 11.9% | NZ$32.80 | NZ$20.14 | n/a | 14 |
| May ’25 | NZ$28.21 | NZ$24.13 -14.5% | 10.0% | NZ$29.10 | NZ$18.40 | n/a | 14 |
| Apr ’25 | NZ$25.65 | NZ$23.91 -6.8% | 9.5% | NZ$28.50 | NZ$18.40 | n/a | 14 |
| Mar ’25 | NZ$24.72 | NZ$22.08 -10.7% | 9.0% | NZ$25.00 | NZ$18.40 | n/a | 14 |
| Feb ’25 | NZ$23.95 | NZ$21.98 -8.2% | 9.1% | NZ$25.00 | NZ$18.40 | n/a | 14 |
| Jan ’25 | NZ$23.60 | NZ$22.11 -6.3% | 8.7% | NZ$25.00 | NZ$18.40 | n/a | 14 |
| Dec ’24 | NZ$23.81 | NZ$22.11 -7.1% | 8.7% | NZ$25.00 | NZ$18.40 | n/a | 14 |
| Nov ’24 | NZ$21.10 | NZ$22.18 +5.1% | 7.9% | NZ$25.00 | NZ$19.45 | NZ$36.07 | 12 |
| Oct ’24 | NZ$21.58 | NZ$22.41 +3.8% | 6.9% | NZ$25.00 | NZ$20.00 | NZ$34.99 | 12 |
| Sep ’24 | NZ$22.50 | NZ$23.21 +3.1% | 10.8% | NZ$28.09 | NZ$20.00 | NZ$35.60 | 12 |
| Aug ’24 | NZ$24.60 | NZ$23.55 -4.3% | 12.0% | NZ$28.09 | NZ$20.00 | NZ$32.85 | 11 |
| Jul ’24 | NZ$24.50 | NZ$23.55 -3.9% | 12.0% | NZ$28.09 | NZ$20.00 | NZ$29.95 | 11 |
| Jun ’24 | NZ$24.38 | NZ$23.55 -3.4% | 12.0% | NZ$28.09 | NZ$20.00 | NZ$29.50 | 11 |
| May ’24 | NZ$27.41 | NZ$24.13 -12.0% | 12.5% | NZ$29.00 | NZ$20.00 | NZ$28.21 | 11 |
| Apr ’24 | NZ$26.65 | NZ$24.03 -9.8% | 12.1% | NZ$29.00 | NZ$20.00 | NZ$25.65 | 11 |
| Mar ’24 | NZ$25.58 | NZ$24.03 -6.1% | 12.1% | NZ$29.00 | NZ$20.00 | NZ$24.72 | 11 |
| Feb ’24 | NZ$25.92 | NZ$24.03 -7.3% | 12.1% | NZ$29.00 | NZ$20.00 | NZ$23.95 | 11 |
| Jan ’24 | NZ$22.60 | NZ$22.56 -0.2% | 12.4% | NZ$27.00 | NZ$18.60 | NZ$23.60 | 12 |
| Dec ’23 | NZ$24.32 | NZ$22.47 -7.6% | 10.4% | NZ$26.00 | NZ$18.60 | NZ$23.81 | 11 |
| Nov ’23 | NZ$20.16 | NZ$21.15 +4.9% | 13.4% | NZ$26.00 | NZ$17.10 | NZ$21.10 | 10 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Third Age Health Services
NZ$22.5m
Provides health care services for residential aged care facilities, private hospitals, and secure dementia in New Zealand.
TAH
NZ$2.26
7D
-3.8%
1Y
45.8%
EBOS Group
NZ$7.3b
Engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand.
EBO
NZ$37.75
7D
3.1%
1Y
7.9%